Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics. This is an ASCO Meeting Abstract from ...

The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, ...

Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT). Background: High-risk clinical stage II melanoma patients ...

Ernexa Therapeutics Inc. ERNA on Wednesday said an independently conducted preclinical study validated the anti-tumor ...

Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...

Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Patients with melanoma who develop cutaneous adverse events (cAEs) during programmed death-1 (PD-1) inhibitor therapy have significantly improved progression-free and overall survival.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...

A fourth of patients with advanced, anti-PD-1-resistant melanoma responded to the viral mimetic BO-112 plus pembrolizumab. Responses were durable with over half of responding patients alive at 24 ...